Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CAPIVASERTIB vs CAPLACIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CAPIVASERTIB vs CAPLACIZUMAB: Safety Overview

Metric CAPIVASERTIB CAPLACIZUMAB
Total FAERS Reports 1,691 145
Deaths Reported 285 34
Death Rate 16.9% 23.4%
Hospitalizations 464 53
Average Patient Age 66.2 yrs 53.0 yrs
% Female Patients 94.6% 51.2%
FDA Approval Date Nov 16, 2023 N/A
Manufacturer AstraZeneca Pharmaceuticals LP Genzyme Corporation
Route ORAL N/A
Marketing Status Prescription N/A